Horizon Beefs Up (While Burning Through Cash)

Before you go, we thought you'd like these...
Before you go close icon

Today, Fool.com health-care analysts Brenton Flynn and David Williamson discuss Horizon Pharmaceuticals and the recent completion of its salesforce rollout for for Duexis. The company expects to reach about 50% of necessary doctors, and Brenton excepts a commiserate acceleration in sales.

Duexis is a crucial drug for the company, but it's burning through cash at the moment and faces generic competition, so this salesforce announcement is more important than just increasing sales: It has huge implications for the company's future viability.


When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

The article Horizon Beefs Up (While Burning Through Cash) originally appeared on Fool.com.

Brenton Flynn, Dave Williamson, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Covidien. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners